Literature DB >> 8389030

The state of p53 in primary human cervical carcinomas and its effects in human papillomavirus-immortalized human cervical cells.

T M Chen1, C A Chen, C Y Hsieh, D Y Chang, Y H Chen, V Defendi.   

Abstract

Wild-type (wt) p53 acts as a tumor suppressor, while certain mutant type (mt) p53 may exhibit 'oncogenic' function. We have recently demonstrated that human papillomavirus type 18 (HPV-18) E6 can partially overcome the growth-suppressive effects of wt p53, but it remains unclear what role p53 plays in cervical carcinogenesis. In this report, we have examined nine HPV-immortalized human cervical epithelial cell lines and 13 HPV-positive and two HPV-negative primary cervical cancers for p53 mutations by polymerase chain reaction--single-strand conformation polymorphism (PCR-SSCP). None of them contained p53 mutations in exons 5-9 where most p53 mutations in human tumors have been found. The entire p53-coding region of the two HPV-negative cervical cancers was sequenced and no mutations were noted. In order to examine the effects of wt p53 and mt p53 on HPV-immortalized human cells, we transfected HPV-immortalized cell lines with wt p53 and a mt p53 (mtp53Val-135). The results indicate that HPV-immortalized cells cannot tolerate large amounts of exogenous wt p53, while mt p53Val-135 can enhance transformation of these cells. The results support the notion that inactivation of wt p53 by E6 may be important for HPV-associated transformation and also suggests that mt p53 can act as an oncogene in HPV-immoralized human cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8389030

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  Immunohistochemical expression of p16 and p53 in vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva.

Authors:  Mauricio Cordoni Nogueira; Ernesto de Paula Guedes Neto; Marcos Wengrover Rosa; Eduardo Zettler; Cláudio Galleano Zettler
Journal:  Pathol Oncol Res       Date:  2006-09-23       Impact factor: 3.201

2.  Use of multiple PCR primer sets for optimal detection of human papillomavirus.

Authors:  F Karlsen; M Kalantari; A Jenkins; E Pettersen; G Kristensen; R Holm; B Johansson; B Hagmar
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

3.  Human papillomavirus DNA and p53 status in stage IB bulky cervical cancer.

Authors:  C A Chen; T M Chen; C C Wu; C F Chang; C Y Hsieh
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

4.  Genetic alterations on chromosome 17p associated with response to radiotherapy in bulky cervical cancer.

Authors:  Y Harima; S Shirahama; K Harima; S Aoki; T Ohnishi; Y Tanaka
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

5.  The role of p53 inactivation in human cervical cell carcinoma development.

Authors:  K Miwa; S Miyamoto; H Kato; T Imamura; M Nishida; Y Yoshikawa; Y Nagata; N Wake
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

6.  Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load.

Authors:  A Helland; F Karlsen; E U Due; R Holm; G Kristensen; A l Børresen-Dale
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.